Pre-made Cinpanemab biosimilar ( Whole mAb, anti-SNCA therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-106
Anti-SNCA therapeutic antibody (Pre-made Cinpanemab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Cinpanemab (BIIB 054), a monoclonal antibody against pathologic alpha-synuclein aggregates, is being developed by Biogen, for the treatment of Parkinson's disease.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-SNCA therapeutic antibody (Pre-made Cinpanemab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||6ct7:HL:AB|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Parkinson's disease|